Dallas, Texas (PRWEB) October 02, 2013
Advances in the Obesity Market helps examine why the obesity market is of such importance across established and emerging economies and how current interventions measure up. In July 2011, the American Association of Clinical Endocrinologists (AACE) reclassified obesity as a diseased state, not a condition, in order to move it up the US healthcare agenda. In 2012, the FDA reviewed its stance on anti-obesity products and approved two new products that were previously declined.
As it stands, there are over 40 medicines currently approved or used off label to treat obesity, in addition there are more than 20 innovative products in clinical development. This new report on advances in the obesity market (http://www.marketreportsonline.com/279318.html ) examines the latest products and devices in development and compares them to those currently available, gathering opinions from key industry leaders to highlight the fast-moving changes that are affecting this profit potential market.
This report provides you with a detailed analysis and key opinions on the current and future obesity market including: Detailed review of the current obesity market, answering ‘Where are we now?’ for both established and emerging economies, Comprehensive insight into newly approved pharmaceuticals and medical devices, analyzing how they compare to established brands, Assessment of key products and devices in development, identifying ‘Ones to Watch’ in late-stage clinical development, Reviews of products and devices that are ‘Waiting in the Wings’ in early-stage clinical development where PoC data is being gathered and Analyses of potential ‘Long Shots’ representing new and innovative products where the rationale has yet to be fully tested.
This report provides a comprehensive overview of ex
Copyright©2012 Vocus, Inc.
All rights reserved